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Abstract
Background: Hyaluronic acid (HA) has been used for target-specific drug delivery because of strong affinity to
CD44, a marker in which overexpressed in cancer cells and cancer stem cells. Conjugation of HA to the cytotoxic
agents via active targeting can improve efficacy, biodistribution, and water solubility. To be able to benefit from
passive targeting as well, a nanoparticulate system by counter ion using a polycation like chitosan may lead to a
perfect delivery system.
Methods: Water soluble Hyaluronic acid-Docetaxel (HA-DTX) conjugate was prepared and used to formulate
chitosan-coated HA-DTX nanoparticles by polyelectrolyte complex (PEC) method and optimized using Box-Behnken
design. Biological evaluation of nanoparticles was done in CD44+ cancer cells.
Results and discussion: Biological evaluation of optimized formula showed IC50 of nanoparticles for 4 T1 and
MCF-7 cell lines were 45.34 μM and 354.25 μM against 233.8 μM and 625.9 μM for DTX, respectively with increased
cellular uptake showed by inverted confocal microscope.
Conclusion: Chitosan-coated HA-DTX nanoparticles were more effective against CD44+ cells than free DTX.
Keywords: Glyconanoparticles, Nanomedicine, Polyelectrolye Complex, Macromolecular Drug Delivery,
Polysaccharides
Background
Most of the anticancer drug products have systemic toxicity
because of the wide uncontrolled distribution in the body.
Besides, their lack of tumor localization and short half-lives
are considerable obstacle facing effective cancer chemother-
apy. Development of nanoparticulate drug delivery systems
and polymer-drug conjugates of low molecular weight cyto-
toxic drug molecules to macromolecular carriers are effect-
ive ways to address these problems by enhanced
permeation and retention (EPR) effect [1, 2]. In addition,
conjugation of cytotoxic drugs to hydrophilic macromole-
cules can increase the water solubility of insoluble drugs
such as docetaxel (DTX) and will enhance their biodistribu-
tion and therapeutic efficacy [3, 4].
DTX is an anticancer agent belongs to the Taxanes
family and is a semi-synthetic derivative from the Taxus
brevifolia [5] DTX shows its cytotoxic effect by inhibit-
ing the depolymerization of microtubules and M-phase
cell arrest [6]. The conventional formulations of DTX in
drug market suffering from low solubility of the active
pharmaceutical ingredient which has been resolved using
tween 80 as surfactant. This issue led to some complica-
tions in the clinic to control formulation-related adverse
drug reactions [7]. Due to the importance of this drug
molecule in chemotherapy protocols, a lot of efforts ded-
icated to address novel formulations of DTX. In one of
these approaches water-soluble macromolecular drug
conjugates has been proposed to prepare tween-free
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formulations along with targeted drug delivery such as
hyaluronic acid-docetaxel (HA-DTX) conjugates. In our
previous report [4], although prepared conjugate had
better solubility profile but the efficacy did not benefit
from its polysaccharide CD44-targeting properties and
heparine like effects of hyaluronic acid in blood circu-
lation. Therefore this report is an attempt to add pas-
sive targeting enhanced permeation and retention of
nanoparticulate system while keeping hyaluronate
moiety. For this purpose, the water soluble conjugate
became coated with chitosan by polyelectrolyte com-
plex (PEC) method to prepare a nanoparticulate drug
delivery system to improve pharmacokinetic features
and efficacy.
For this purpose, hyaluronic acid (HA) as one of the
common polysaccharides carriers has been used for con-
jugation of low molecular weight cytotoxic drugs such as
DTX. HA is biocompatible, biodegradable and non-
immunogenic [8]. The most considerable advantage of
HA is its strong affinity for CD44, a cell surface protein
which is overexpressed in many cancer cells and cancer
stem cells [9, 10]. CD44 is a specific biological receptor
for HA [11, 12]. HA could have an enhanced attachment
and uptake into malignant cells with metastatic activities
[13] and has been used for target-specific drug delivery
[14, 15]. We hypothesized using HA as carrier and tar-
geting moiety simultaneously may reverse the multiple
drug resistance of cancer stem cells via affecting CD44
and regarding physical correlation of P-gp and these
markers [16]. In this regard, HA-DTX conjugates has
been prepared and evaluated which showed suitable effi-
cacy and safety profile. This research reports optimized
polyelectrolyte complex nanoparticles using HA-DTX as
cationic part.
Polyelectrolyte complexes which were prepared by
electrostatic interaction between unlike charged poly-
ions have received substantial attention in drug delivery
systems. The synthesis of PEC nanoparticles is simple
and can be easily carried out under mild conditions
without using toxic organic solvents or chemical cross-
linkers [17]. In the present study, chitosan as a N-
deacetylated derivative of chitin has been used exten-
sively as a biocompatible polysaccharide [18] with a
cationic nature that can be protonated in weak acidic
environment [19], and therefore it can improve the
bioavailability of DTX [20].
Achieving optimization of the nanoparticle prepar-
ation could be performed by classical method of
changing one variable at a time while others have
been remained constant. However this method needs
lots of series of experiments and time. Moreover in
this approach the possible interaction between inde-
pendent factors will not be observed. Therefore, the
fine optimized formulation will not be achieved.
Design-of-experiment (DoE) method has been used
in pharmaceutical studies to solve this problem.
Optimization by response surface methodology in-
cluding Box-Behnken method is considered as the
major application of DoE [21, 22].
In the present study, the water soluble conjugated
HA-DTX was synthesized. Then, chitosan coated HA-
DTX nanoparticles were prepared by PEC method
considering the anionic structure of HA-DTX and cat-
ionic chitosan. Box-Behnken statistical design using a
response surface methodology has been employed to ob-
tain the optimized condition in terms of particle size,
size distribution, drug loading and zeta potential. For
determination of efficacy of optimized chitosan coated
HA-DTX conjugate nanoparticles, 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was
performed on MCF-7, human cancer cell line, and 4 T1
mouse breast cancer cell line. MCF-7 and 4 T1 cell lines
were also used for cell uptake study.
Materials and methods
Materials
Sodium hyaluronate (MW 25 kDa) was purchased from
GuangLong (Shandong, China). Anhydrous DTX was
purchased from Jiangsu Yew (Jiangsu, China). Chitosan
(MW 50 kDa, (Primex, Karmoy, Norway), 1-Ethyl–3-[3-
(dimethylamino)-propyl] carbodiimide (EDC), N-hydroxy
succinimide (NHS), 4’,6-diamidino-2-phenylindole (DAPI)
and triethylamine were purchased from Sigma Aldrich
(Seelze, Germany). MTT dye was from Merck (Darmstadt,
Germany). Dulbecco's Modified Eagle Medium (DMEM)
with high glucose, RPMI 1640, FBS (Fetal Bovine Serum),
trypsin, penicillin and streptomycin were purchased from
Biosera (Vienna, Austria). Ultra-purified water was used
throughout the analysis and all other chemicals were of
analytical grade. 4 T1 and MCF-7 cell lines were obtained
from National Cell Bank of Iran (Pasteur Institute of Iran,
Tehran, Iran).
Methods
Synthesis of hyaluronic acid-docetaxel (HA-DTX)
conjugates
At first for preparing desalted HA, HA (MW 25 kDa)
(1 g) was dissolved in 100 mL of deionized water, then
the solution was dialyzed (MWCO 12 kDa) in deionized
water for 24 h and lyophilized [23].
Desalted-HA (400 mg) was dissolved in 80 mL of de-
ionized water. Then EDC and NHS were added to the
solution in 11 and 10 molar ratios of carboxyl groups of
HA, respectively. The mixture was stirred at 40 °C for
3 h. Then 80 mL dimethylformamide (DMF) containing
400 mg of DTX and 20 mL of triethylamine were added.
After 24 h the mixture was refluxed at 70 °C and after
cooling to room temperature was transferred to pretreat
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dialysis tubing (MWCO 3500 kDa). The mixture was
purified by dialysis against water-acetone solution
(50:50, v/v) for 1 h, water-acetone (75:25, v/v) for
1 h and water for 1 h, respectively. The obtained
HA-DTX conjugate is water soluble. To eliminate
the remained DTX, the mixture was transferred to a
separating funnel and extracted three times with di-
chloromethane. The aqueous phase was lyophilized.
Chemical integrity of the resulted product was
checked by 1H-NMR (Bruker AC 500 Spectropho-
tometer, Germany) and fourier transform infra-red
(FTIR) spectroscopy (Nicolet Magna-FTIR 550 Spectrom-
eter, WI, USA). The concentration of DTX was measured
by UV Spectrophotometry (UV-visible Spectrophotometer,
160A, SHIMADZU, Japan) at 229 nm versus a suitable
blank solution containing the appropriate concentra-
tion of HA.
Preparation of chitosan coated HA-DTX conjugate
nanoparticle
Chitosan coated HA-DTX conjugate nanoparticles were
prepared by PEC method, considering the anionic
structure of HA-DTX conjugates and cationic chitosan
[24]. As a representative example, 1 mL of aqueous
solution of HA-DTX (4.25 mg/mL) was added slowly
to 1 mL of dilute chitosan solution (0.250 mg/mL of
1 % acetic acid) in 1 min while stirring at 370 rpm at
room temperature. It should be mentioned that dur-
ing the screening and optimization procedure, various
factors including ratios of HA-DTX conjugate to chi-
tosan, stirring rate and temperature were evaluated.
DTX determination in the conjugates and nanoparticles
The concentration of DTX in conjugate was mea-
sured by UV spectrophotometry. Determination of
DTX in prepared nanoparticles was performed by
UV absorbance at 229 nm to determine drug loading
and entrapment efficiency. The final solution of chi-
tosan coated HA-DTX nanoparticles were transferred
to microtubes and centrifuged by an ultracentrifuge
(Optima MAX-XP Ultracentrifuge, Beckman Coulter,
USA) at 22000 rpm (150700 g) for 20 min at 10 °C.
After collecting the supernatant, the free remaining
non-conjugated DTX in the reaction medium was
measured by UV spectrophotometry. The encapsu-
lated efficiency and DTX loading in nanoparticles
were calculated, applying the following equations:
Fourier transform infra-red spectroscopy of conjugates
Freeze-dried conjugated HA-DTX, HA, DTX were ana-
lyzed by FTIR Spectrometer. The data was achieved in
the range of 400–4000 cm−1 for each sample. The FTIR
spectra of conjugated HA-DTX were compared with
pure substances.
Experimental design studies
Box-Behnken statistical design which is a response sur-
face methodology has been employed in the present
study. In this study the effect of three quantitative inde-
pendent variables consisting of stirring rate (rpm), ratio
of HA-DTX conjugate to chitosan and temperature (°C)
were investigated on dependent variables and responses,
including particle size (nm), zeta potential (mv), polydis-
persity index (PdI) and DTX loading in nanoparticles
with Design Expert software (V. 7.0.0, Stat-Ease Inc.,
Minneapolis, USA). Dependent and independent vari-
ables were elucidated based on the preliminary studies
which are shown in Table 1.
The aim of the design was to achieve to the optimum
formulation, with both minimum size and maximum
loading. The PdI factor should be at possible lowest level
and zeta potential should be appropriate to have stable
nanoparticles. Obtained responses from three optimized
formulations were compared with the suggested experi-
mental responses to evaluate the precision of model.
Characterization of the nanoparticles
The size and zeta potential of the nanoparticles were de-
termined using a Zetasizer Nano ZS Analyzer (Malvern
Instruments, UK) with a He-Ne laser beam at wave-
length of 633 nm at 25 °C.
Surface morphology of the nanoparticles observed
using Scanning Electron Microscopy (SEM) (Philips
Xl30, The Netherlands) and Atomic Force Microscopy
(AFM) (dualscope™ DS 95-200/50, Denmark) micros-
copy. For AFM evaluation, one drop of nanoparticle sus-
pension was dried on the surface of clean silicon wafer
at room temperature. AFM study was performed with
20 μm scanner in tapping mode. For SEM imaging, dried
nanoparticles were gently coated by gold layer with a
sputter coater and evaluated at 30 kV using a 6300 field
emission scanning electron microscope.
Differential scanning calorimetry (DSC) was per-
formed using Mettler-Toledo DSC822e (Greifensec,
Switzerland) and data acquisition and analysis was car-
ried out by a software package of STARe 9.01. The
Entrapment efficiency %ð Þ ¼ Total amount of DTX−Amount of DTX in supernatant
Total amount of DTX
 100
Drug loading %ð Þ ¼Weight of drug found loaded
Weight of nanoparticle
 100
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system was conducted by using 8 mg of sample, depos-
ited in 40 μL aluminum pans and hermetically sealed,
under a nitrogen gas dynamic flow at a scanning heating
rate of 10 °C/min over a range of 20 °C to 300 °C. Empty
hermetically sealed aluminum pan was used as a control.
Cytotoxicity evaluation of nanoparticles
For cytotoxicity study of nanoparticles, MTT assay was
performed on MCF-7, human breast cancer cell line,
and 4 T1 mouse breast cancer cell line [25]. Cell culture
medium was DMEM with 10 % FBS and 5 % penicillin-
streptomycin. Cells maintained at 37 °C and humidified
environment with 5 % CO2. Cells were seeded into 96-
well plate separately at a seeding density of 5000 cell/
well. After 24 h incubation, various concentrations of
free DTX and nanoparticles (0.1, 10, 100, 500, 1000, and
1500 μM) (based on DTX equivalent concentration)
were used as treatments and incubated for 48 h. Then
50 μL MTT (1 mg/mL) solution in PBS was added to
each well and incubated for 4 h. Formazan precipitates
dissolved by 150 μM dimethyl sulfoxide (DMSO). The
absorption was measured at 570 nm and reference well
at 620 nm by ELISA reader [26]. Cell viability was
calculated by the following equation where OD is op-
tical density:
Cell viability% ¼ ODtest well= ODreference wellð Þ x 100
Preparation of fluorescent-labeled HA
To prepare fluorescent-labeled HA conjugate, HA was
labeled with fluorescamine. One hundred mg of HA was
dissolved in 10 mL water and 61.5 mg of EDC and
45.5 mg of NHS were added. The mixture was stirred
for 3 h and then 45.84 mg fluorescamine was added and
stirred for 24 h. The reaction flask was protected from
light by covering with an aluminum foil. After 24 h the
mixture was purified by dialysis (MWCO 3500) against
deionized water and finally the product was freeze-dried.
Fluorescent-labeled nanoparticles were also prepared by
fluorescent-labeled HA conjugate instead of HA-DTX
conjugate and the nanoparticle preparation method was
the same as the optimized method used for normal
nanoparticles.
Cell uptake studies
In order to study the cellular uptake of the nanoparti-
cles, 4 T1 and MCF-7 cell lines were seeded at 1 × 105
cell/well in a cover glass and incubated at 37 °C with
5 % CO2 atmosphere for 24 h. After complete adhesion,
the medium was carefully removed and replaced with
fresh medium containing fluorescent-labeled nanoparti-
cles and incubated for 2 h. In this stage, the medium
containing drug was removed and cells were washed 4
times with PBS and fixed with formaldehyde 4 % for
4 min. Nuclear coloring was performed with DAPI
(0.5 mg/mL) in 5 min and then cells were washed 4
times with PBS using inverted confocal microscope
(Nikon ECLIPSE Ti, Tokyo, Japan) cell images were
taken [27].
Statistical analysis
SPSS 20.0 statistical software and one-way analysis of
variance (ANOVA) were used to assess the data groups.
All the results were evaluated as mean ± standard
deviation (SD). Significance difference of p < 0.05 was
accepted.
Results and discussion
Synthesis and characterization of water-soluble HA-DTX
direct conjugate
Indirect HA-DTX conjugate was synthetized previously
in our group. Conjugation of DTX in these studies needs
preparation of succinyl DTX [4, 28]. The direct forma-
tion of conjugated HA-DTX has been reported for the
first time with fewer procedure steps (Fig. 1). An esteric
bound formed between 2´-OH of DTX and COOH of
HA [29]. Formation of conjugated HA-DTX was con-
firmed by the presence of aromatic protons in 1H-NMR
spectra (Fig. 2). FTIR of freeze-dried HA-DTX conju-
gate, pure HA, pure DTX were also obtained (Fig. 3).
DTX had a specific peak in 1242 cm−1 which had no
interaction with HA specific peak. This peak has been
repeated in HA-DTX conjugate spectrum with a little
shift to 1249 cm−1. Presence of this peak and HA related
peaks in conjugate spectrum confirms the formation of
HA-DTX conjugate.
The absorption of DTX in conjugate was measured by
UV spectroscopy. According to UV absorption, it was
shown that 1 mg of HA-DTX conjugate contains 69 μg
of DTX.
Preparation of chitosan coated HA-DTX conjugate
nanoparticle
Publications reported several nanoparticular based
methods to improve DTX drug delivery to cancer cells
(DTX loaded chitosan nanoparticle [30], targeted DTX
nanoparticles with different targeting agents like folic
acid [2] and albumin nanoparticles of DTX [28]). HA
Table 1 Variables used in Box-Behnken experimental design
Independent factors Factor level Dependent factors
Numeric Factors −1 0 1 Particle size (nm)
Stirring rate (rpm) 300 800 1300 Zeta potential (mv)
Ratio of HA-DTX
conjugate to chitosan
13 17 21 Polydispersity index (PdI)
Temperature (°C) 0 25 50 Drug content or DTX
loading (%)
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Fig. 1 Schematic representation of hyaluronic acid-docetaxel (HA-DTX) conjugate and chitosan coated HA-DTX nanoparticles preparation
Fig. 2 Formation of hyaluronic acid-docetaxel (HA-DTX) conjugate was confirmed by the presence of aromatic protons in 1H-NMR spectra
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could cause heparin-induced thrombocytopenia because
of its nature as a polysaccharide [31]. This event should
be considered if the HA-DTX used alone. Coating the
HA-DTX conjugate with chitosan may limit the expos-
ure of HA with platelet in blood circulation and reduce
thrombocytopenia. Chitosan-coated HA-DTX conjugate
nanoparticles were prepared based on these findings.
Optimization studies
To obtain an optimized formulation of HA-DTX nanopar-
ticles, Box-Behnken statistical design was used. Table 2
shows 17 runs based on Box-Behnken design to analyze
the effects of independent variables on dependent vari-
ables and the data achieved to find out optimized
formulation.
As a result, 17 runs were needed to achieve the opti-
mized formulation and the second-order polynomial
functions explained the relationship between the
dependent and the independent variable as following
equation:
Fig. 3 FTIR spectrum of (a) docetaxel (DTX); b hyaluronic acid (HA); c hyaluronic acid-docetaxel (HA-DTX) conjugate
Y1; 2; 3 ¼ b0 þ b1Aþ b2Bþ b3Cþ b11A2 þ b22B2
þ B33C2 þ b12ABþ b13ACþ b23BC
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which A, B and C are independent variables, and Y is
the predicted dependent factor, b0 is the intercept, b1,
b2, and b3 are linear coefficients, b11, b22, and b33 are
squared coefficients, and b12, b13, and b23 are the inter-
action coefficients of equation.
Size of nanoparticles
Size is the most important parameter in determining the
nanoparticles cellular uptake. Nanoparticles were opti-
mized to achieve minimum size while the PdI kept at
minimum and loading maximum. As seen in Fig. 4a in
the middle range of stirring rate, size of nanoparticles
would be reduced. Higher stirring rate could generate
bubble and solution splashing so it could not prepare
suitable particles. It seems stirring rate at lower limit do
not supply enough energy to product small particles, so
enlargement has seen in this rate. Figure 4b represents
that by increasing the ratio of HA-DTX to chitosan, the
size of nanoparticles would be increased. Temperature
had minor effect on the size of nanoparticles.
Particle size ¼ 191þ 64A‐27:63B‐3:87Cþ 48:62A2
þ 31:38B2‐19:13C2
Polydispersity index
Polydispersity index represents the homogeneity of nano-
particles and changs between of 0 to 1 with a desire to be
near 0. The less PdI value indicates the more size uniform-
ity in nanoparticle. As shown in Fig. 4c by increasing the
temperature, PdI reduced and it would be at minimum of
50 °C. On the other hand, lower PdI is observed in the
middle range of stirrer rate. Figure 4d represents that by
increasing the ratio of HA-DTX to chitosan, PdI would be
decreased.
PdI ¼ 0:055‐0:041A‐0:00563B‐0:00613Cþ 0:022BC
þ 0:02A2 þ 0:013B2‐0:014C2
Drug content
Higher amount of drug content is desired and repre-
sented an acceptable formulation strategy. HA-DTX to
chitosan ratio was the most important factor in drug
content. By increasing the ratio of HA-DTX to chitosan,
higher drug content would be obtained.
Drug content ¼ 3:16þ 0:099A
þ 0:000125C‐0:018A2‐0:00138C2
Confirmation of designed optimized experiments
After analyzing data and 3D diagrams by utilizing Box-
Behnken method, an optimized formulation achieved
which the independent variables were 18.5 for ratio of
HA-DTX to chitosan, 723 rpm for stir rate and 50 °C
for temperature. It also predicted the amount of
Table 2 The effect of independent variables on dependent variables
Run Independent variables Dependent variables
Stirring rate (rpm) Ratio of HA-DTX
conjugate
to chitosan
Temperature (°C) Particle size (nm) Zeta potential (mv) Polydispersity
index (PdI)
DTX loading (%)
1 300.00 13.00 25.00 195 21.7 0.128 3.043
2 300.00 21.00 25.00 444 18.6 0.065 3.257
3 1300.00 13.00 25.00 176 22.3 0.129 3.034
4 1300.00 21.00 25.00 269 17.4 0.030 3.235
5 800.00 13.00 0.00 174 22.3 0.120 3.042
6 800.00 21.00 0.00 280 18.0 0.019 3.235
7 800.00 13.00 50.00 182 21.9 0.086 3.048
8 800.00 21.00 50.00 246 19.2 0.019 3.233
9 300.00 17.00 0.00 210 21.3 0.083 3.159
10 1300.00 17.00 0.00 199 19.6 0.033 3.161
11 300.00 17.00 50.00 210 21.3 0.031 3.157
12 1300.00 17.00 50.00 194 24.1 0.070 3.160
13 800.00 17.00 25.00 195 21.3 0.061 3.160
14 800.00 17.00 25.00 191 21.6 0.039 3.160
15 800.00 17.00 25.00 179 22.7 0.064 3.159
16 800.00 17.00 25.00 193 21.1 0.045 3.159
17 800.00 17.00 25.00 197 21.3 0.067 3.159
Shabani Ravari et al. DARU Journal of Pharmaceutical Sciences  (2016) 24:21 Page 7 of 12
dependent factors would be 205 nm for size of nano-
particles, 0.02 for PdI and 3.19 % for DTX content
and +21.5 mV for zeta potential. Analysis of variance
(ANOVA) and lack of fit parameters for the responses
according to quadratic model is provided in Table 3.
Three experiments were performed in the lab ac-
cording to the optimized formulation and there was
no significant difference between the obtained and
predicted results. The mean amount obtained in these
experiments was 234 nm for size of nanoparticles,
0.088 for PdI and 3.18 % for DTX content and
+20.03 mV for zeta potential. The mean entrapment
efficiency for these experiments was 62.78 %. The
entrapment efficiency showed that nanoparticles could
be an effective carrier for DTX.
Characterization of nanoparticles
Particle size,distribution and zeta potential
Particle size and size distribution of nanoparticles were
measured by dynamic light scattering (DLS). The mean
obtained size and PdI of the optimized chitosan coated
HA-DTX conjugate nanoparticles were 234 nm and
0.088 respectively (Fig. 5a). Zeta potential of optimized
nanoparticles was +20.03 mV which showed complete
chitosan coating (Fig. 5b). This amount of zeta potential
could provide the appropriate repulsive force to prevent
Table 3 Analysis of variance (ANOVA) and lack of fit parameters for the responses according to quadratic model
Parameters Source Sum of squares Degrees of freedom (df) Mean squares F value P-value
Particle Size Quadratic vs 2FI 15730.13 3 5243.38 4.93 0.0378
Zeta Potential Quadratic vs 2FI 8.71 3 2.9 5.3 0.0321
PdI Quadratic vs 2FI 3.11E-03 3 1.04E-03 9.9 0.0065
Drug Loading Quadratic vs 2FI 1.46E-03 3 4.86E-04 9.99 0.0063
Lack of Fit
Particle Size Quadratic 7239.25 3 2413.08 48.26 0.0013
Zeta Potential Quadratic 2.2 3 0.73 1.79 0.2889
PdI Quadratic 1.16E-04 3 3.86E-05 0.25 0.8579
Drug Loading Quadratic 3.39E-04 3 1.13E-04 376.94 0.0001
Fig. 4 Response surface plots showing the effect of different independent factors on (a) (b) size of nanoparticles; c, d polydispersity index
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Fig. 5 Nanoparticles characterization: a particle size and distribution; b zeta potential; c SEM picture; d AFM micrographs
Fig. 6 DSC thermogram of freeze-dried nanoparticles, hyaluronic acid-docetaxel (HA-DTX) conjugate, pure chitosan, pure hyaluronic acid (HA),
pure docetaxel (DTX) and physical mixture of HA-DTX conjugate and chitosan
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nanoparticle aggregation and improv the stability of
formulation.
Differential scanning calorimetry
Freeze-dried nanoparticles, conjugated HA-DTX, chito-
san, HA, DTX and physical mixture of HA-DTX conju-
gate and chitosan was analyzed during predetermined
increasing temperature rate to obtain DSC thermogram.
The DSC thermograms of DTX exhibit an endothermic
peak showed melting around 170 °C. HA exhibited one
exothermic peak presenting crystallization around 230 °C.
Characteristic peaks of DTX and HA were not exist in the
thermograms of conjugated HA-DTX. These findings con-
firm the development of HA-DTX conjugate (Fig. 6) [32].
DSC thermogram specificities of HA has an influence
on DSC thermogram of physical mixture of HA-DTX
conjugate and chitosan. Because of the ionic charge of the
chitosan (cationic) and HA (anionic), these two com-
pounds can form a charge-transfer bond (the same as
PEC formation) which may attenuate the difference in
comparing these physical mixture and polyelectrolyte
complex. So, DSC thermogram of nanoparticles may
not express this influence. These results revealed that
chitosan coated nanoparticles protected conjugated
HA-DTX and weakened the effect of temperature,
which showed the formation of chitosan coated HA-
DTX nanoparticles.
Nanoparticle morphology
Chitosan coated HA-DTX nanoparticles were morpho-
logically studied by SEM and AFM. SEM showed
(Fig. 5c) that nanoparticles are uniform spheres and
Fig. 7 In vitro cell studies: a MTT assay of DTX and nanoparticles on 4 T1 cells (blue bar for nanoparticle and red bar for DTX); b MTT assay of
DTX and nanoparticles on MCF-7 cells (blue bar for nanoparticle and red bar for DTX); c uptake image of 4 T1 cell line (nuclear coloring with DAPI,
FITC labeled chitosan coated HA-DTX conjugate nanoparticles, merge image of DAPI and FITC labeled chitosan coated HA-DTX conjugate
nanoparticles and control cell) and uptake image of MCF7 cell line (nuclear coloring with DAPI, FITC labeled chitosan coated HA-DTX con-
jugate nanoparticles, merge image of DAPI and FITC labeled chitosan coated HA-DTX conjugate nanoparticles and control cell); *p < 0.05;
**p < 0.01; ***p < 0.001
Shabani Ravari et al. DARU Journal of Pharmaceutical Sciences  (2016) 24:21 Page 10 of 12
non-aggregated. AFM micrographs (Fig. 5d) confirmed
the spherical shape of nanoparticles too.
In vitro cytotoxicity
The cytotoxicity of chitosan coated HA-DTX nanoparti-
cles and DTX were assessed by MTT assay on 4 T1 and
MCF-7 cell lines. By increasing the amount of nanopar-
ticles or free DTX the cytotoxicity increased. The calcu-
lated IC50 of chitosan coated HA-DTX conjugate
nanoparticles for 4 T1 and MCF-7 cell lines were
45.34 μM and 354.25 μM respectively while 233.8 μM
and 625.9 μM for DTX on 4 T1 and MCF-7 cell lines
after 48 h incubation. DTX loaded chitosan nanoparti-
cles were more effective against cancer cells than free
DTX drug [30]. Being agree to this result in our study
cell viability (%) and IC50 of optimized nanoparticles
were less than free drug. It may be because of higher
DTX concentration which was available in intracellular
space. Small size of nanoparticle as a passive targeting,
effect of HA and the adhesive effect of chitosan coat
may cause this availability. Therefore, nanoparticles were
more potent than free DTX in cytotoxic effect on 4 T1
and MCF-7 cells (Figures 7a, b).
Cell uptake studies
Entrance of nanoparticles in cancer cells had a direct re-
lation with their observed cytotoxic effect. Free DTX
molecules could be transported out by P-glycoprotein
(P-gp) pumps, but drug loaded nanoparticles were taken
up by cells through an endocytosis pathway. The result
represented higher cellular uptake of nanoparticles
because of their ability to escape from the effect of P-gp
pumps [33]. The uptake of optimized FITC-labeled
chitosan-coated HA-DTX conjugate nanoparticles by
4 T1 and MCF-7 after 24 h incubation is shown in
Fig. 7c. No treatment cells of each cell line are presented
in Fig. 7c as a control. Based on fluorescence intensity,
FITC-labeled chitosan-coated HA-DTX nanoparticles
showed appropriate entrance into 4 T1 and MCF-7 cells.
As a result it can be proposed that developed nanoparti-
cles could bring loaded drug molecules effectively to cell
cytoplasm as a novel drug delivery system.
Conclusion
Water soluble HA-DTX conjugate was prepared accord-
ing to HA strong affinity for CD44, a cell surface protein
which is overexpressed in many cancer cells and cancer
stem cells. Chitosan-coated HA-DTX nanoparticles by
polyelectrolyte complex method improved DTX availabil-
ity. The fine optimized formulation was achieved with
proper particle size, PdI, zeta potential and drug loading.
The biological evaluation of nanoparticles showed they
were more potent than free DTX in cytotoxic effect on
MCF-7 and 4 T1 cells beside of their appropriate entrance
in to cells. These findings need further evaluation to take
into account potential improved pharmacokinetic of
nanoparticulate drug delivery system.
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